We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+29.49%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.24B
AUM Growth
+$210M
Cap. Flow
-$9.44M
Cap. Flow %
-0.76%
Top 10 Hldgs %
95.45%
Holding
16
New
3
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$69.1M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$15.5M
3
AERI
Aerie Pharmaceuticals
AERI
+$10.6M
4
FLXN
Flexion Therapeutics, Inc.
FLXN
+$9.06M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$1.87M

Top Sells

Rank Stock Value
1
INGN icon
Inogen
INGN
+$45.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$41.8M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 57.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$652B
$316M 25.55%
2,979,100
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$265M 21.42%
5,901,819
-995,000
-14% -$41.8M
INGN icon
3
Inogen
INGN
$172M
$111M 9.01%
3,549,320
-1,870,129
-35% -$45.3M
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30B
$110M 8.91%
2,101,000
– –
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
$93.1M 7.53%
3,201,183
– –
NVRO
6
DELISTED
NEVRO CORP.
NVRO
$84.9M 6.87%
+2,194,841
New +$69.1M
OTIC
7
DELISTED
Otonomy, Inc.
OTIC
$72.5M 5.86%
2,175,025
– –
TTPH
8
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$58.6M 4.74%
73,750
+28,750
+64% +$15.5M
FLXN
9
DELISTED
Flexion Therapeutics, Inc.
FLXN
$46.1M 3.73%
2,283,131
+500,000
+28% +$9.06M
AKBA icon
10
Akebia Therapeutics
AKBA
$341M
$17.7M 1.43%
1,516,387
– –
ELDN icon
11
Eledon Pharmaceuticals
ELDN
$276M
$17.4M 1.41%
7,278
+642
+10% +$1.52M
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$12.3M 0.99%
+419,652
New +$10.6M
XENT
13
DELISTED
Intersect ENT, Inc
XENT
$6.49M 0.53%
350,000
– –
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.32B
$2.52M 0.2%
+127,563
New +$1.87M
ZSPH
15
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-506,730
Closed -$19.9M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q4 2014 Portfolio in Review

As of Q4 2014, Novo Holdings A/S held 16 positions worth $1.24B, up 21% from $1.03B the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Novo Holdings A/S's Q4 2014 filing shows 3 new, 3 increased, 2 reduced and 1 closed positions. Its largest new stake was NEVRO CORP.: 2,194,841 shares worth $84.9M. The largest sale was Inogen, an estimated $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 54% a quarter earlier.

  • Novo Holdings A/S's largest Q4 2014 buy was NEVRO CORP.: 2,194,841 shares worth $84.9M.
  • Novo Holdings A/S added most to Tetraphase Pharmaceuticals, Inc. in Q4 2014, an estimated $15.5M increase.
  • Novo Holdings A/S's biggest Q4 2014 reduction was Inogen, cutting an estimated $45.3M.
  • Novo Holdings A/S fully exited ZS PHARMA INC COMS TK (DE) in Q4 2014, selling an estimated $19.9M.
  • Novo Holdings A/S's ten largest holdings make up 95% of its $1.24B portfolio in Q4 2014.
  • Novo Holdings A/S opened 3 new positions and closed 1 in Q4 2014.
  • Novo Holdings A/S's portfolio value rose 21% quarter-over-quarter to $1.24B.

Based on Novo Holdings A/S's 13F filing for Q4 2014, filed 17 Feb 2015.